Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026
Roche will present new data from the Phase II studies of enicepatide and petrelintide in obesity at the ADA Scientific Sessions.
Therapeutic Area
Therapeutic area intelligence for Peptide Therapy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.